ACRS · Aclaris Therapeutics Inc
United States · RS rating 33 · As of 2026-11-03
| Price | 3.74 USD |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 33 / 31 / 13 / 85 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 33 / 28 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | -33.3% |
| Sales growth Q/Q | -60.8% |
| Distance from 52-week high | +42.8% |
| Market cap (USD) | $635.5M |